Literature DB >> 27852701

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.

Chelsea Bolyard1,2, W Hans Meisen1,2, Yeshavanth Banasavadi-Siddegowda1,2, Jayson Hardcastle1, Ji Young Yoo1,2, Eric S Wohleb3, Jeffrey Wojton1, Jun-Ge Yu2,4, Samuel Dubin1,2, Maninder Khosla2,4, Bo Xu2, Jonathan Smith1, Christopher Alvarez-Breckenridge1,2, Pete Pow-Anpongkul1,2, Flavia Pichiorri5, Jianying Zhang2,6, Matthew Old2,4, Dan Zhu7, Erwin G Van Meir7, Jonathan P Godbout2,3, Michael A Caligiuri2, Jianhua Yu2, Balveen Kaur8,2.   

Abstract

Purpose: Brain angiogenesis inhibitor (BAI1) facilitates phagocytosis and bacterial pathogen clearance by macrophages; however, its role in viral infections is unknown. Here, we examined the role of BAI1, and its N-terminal cleavage fragment (Vstat120) in antiviral macrophage responses to oncolytic herpes simplex virus (oHSV).Experimental Design: Changes in infiltration and activation of monocytic and microglial cells after treatment of glioma-bearing mice brains with a control (rHSVQ1) or Vstat120-expressing (RAMBO) oHSV was analyzed using flow cytometry. Co-culture of infected glioma cells with macrophages or microglia was used to examine antiviral signaling. Cytokine array gene expression and Ingenuity Pathway Analysis (IPA) helped evaluate changes in macrophage signaling in response to viral infection. TNFα-blocking antibodies and macrophages derived from Bai1-/- mice were used.
Results: RAMBO treatment of mice reduced recruitment and activation of macrophages/microglia in mice with brain tumors, and showed increased virus replication compared with rHSVQ1. Cytokine gene expression array revealed that RAMBO significantly altered the macrophage inflammatory response to infected glioma cells via altered secretion of TNFα. Furthermore, we showed that BAI1 mediated macrophage TNFα induction in response to oHSV therapy. Intracranial inoculation of wild-type/RAMBO virus in Bai1-/- or wild-type non-tumor-bearing mice revealed the safety of this approach.Conclusions: We have uncovered a new role for BAI1 in facilitating macrophage anti-viral responses. We show that arming oHSV with antiangiogenic Vstat120 also shields them from inflammatory macrophage antiviral response, without reducing safety. Clin Cancer Res; 23(7); 1809-19. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27852701      PMCID: PMC5380537          DOI: 10.1158/1078-0432.CCR-16-1818

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  46 in total

1.  Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide.

Authors:  Y Huang; C J Henry; R Dantzer; R W Johnson; J P Godbout
Journal:  Neurobiol Aging       Date:  2007-05-31       Impact factor: 4.673

2.  Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.

Authors:  K-W Peng; R Myers; A Greenslade; E Mader; S Greiner; M J Federspiel; A Dispenzieri; S J Russell
Journal:  Gene Ther       Date:  2012-04-05       Impact factor: 5.250

3.  Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Authors:  Ji Young Yoo; Amy Haseley; Anna Bratasz; E Antonio Chiocca; Jianying Zhang; Kimerly Powell; Balveen Kaur
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

4.  Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Authors:  Chelsea Bolyard; Ji Young Yoo; Pin-Yi Wang; Uksha Saini; Kellie S Rath; Timothy P Cripe; Jianying Zhang; Karuppaiyah Selvendiran; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

5.  Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.

Authors:  Jula Veerapong; Kai A Bickenbach; Michael Y Shao; Kerrington D Smith; Mitchell C Posner; Bernard Roizman; Ralph R Weichselbaum
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

6.  Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance.

Authors:  Amy Haseley Thorne; Walter H Meisen; Luke Russell; Ji Young Yoo; Chelsea M Bolyard; Justin D Lathia; Jeremy Rich; Vinay K Puduvalli; Hsiaoyin Mao; Jianhua Yu; Michael A Caligiuri; Susheela Tridandapani; Balveen Kaur
Journal:  Mol Ther       Date:  2014-06-04       Impact factor: 11.454

7.  Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer.

Authors:  Y Fukushima; Y Oshika; T Tsuchida; T Tokunaga; H Hatanaka; H Kijima; H Yamazaki; Y Ueyama; N Tamaoki; M Nakamura
Journal:  Int J Oncol       Date:  1998-11       Impact factor: 5.650

8.  Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP.

Authors:  Huiqing Fang; Ruma A Pengal; Xianhua Cao; Latha P Ganesan; Mark D Wewers; Clay B Marsh; Susheela Tridandapani
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

9.  Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.

Authors:  Philip A Klenotic; Ping Huang; Juan Palomo; Balveen Kaur; Erwin G Van Meir; Michael A Vogelbaum; Maria Febbraio; Candece L Gladson; Roy L Silverstein
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

10.  Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia.

Authors:  Christopher J Henry; Yan Huang; Angela Wynne; Mark Hanke; Justin Himler; Michael T Bailey; John F Sheridan; Jonathan P Godbout
Journal:  J Neuroinflammation       Date:  2008-05-13       Impact factor: 8.322

View more
  15 in total

1.  Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy.

Authors:  Yangjin Kim; Ji Young Yoo; Tae Jin Lee; Joseph Liu; Jianhua Yu; Michael A Caligiuri; Balveen Kaur; Avner Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

Review 2.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 3.  Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.

Authors:  Yoshihiro Otani; Ji Young Yoo; Toshihiko Shimizu; Kazuhiko Kurozumi; Isao Date; Balveen Kaur
Journal:  Brain Tumor Pathol       Date:  2022-04-06       Impact factor: 3.298

4.  NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.

Authors:  Yoshihiro Otani; Ji Young Yoo; Cole T Lewis; Samantha Chao; Jessica Swanner; Toshihiko Shimizu; Jin Muk Kang; Sara A Murphy; Kimberly Rivera-Caraballo; Bangxing Hong; Joseph C Glorioso; Hiroshi Nakashima; Sean E Lawler; Yeshavanth Banasavadi-Siddegowda; John D Heiss; Yuanqing Yan; Guangsheng Pei; Michael A Caligiuri; Zhongming Zhao; E Antonio Chiocca; Jianhua Yu; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2022-04-01       Impact factor: 13.801

Review 5.  Adhesion G protein-coupled receptors: structure, signaling, physiology, and pathophysiology.

Authors:  Trisha Lala; Randy A Hall
Journal:  Physiol Rev       Date:  2022-04-25       Impact factor: 46.500

6.  Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.

Authors:  Michael A Giacomantonio; Andra M Sterea; Youra Kim; Joao A Paulo; Derek R Clements; Barry E Kennedy; Moamen J Bydoun; Ge Shi; David M Waisman; Steven P Gygi; Carman A Giacomantonio; J Patrick Murphy; Shashi Gujar
Journal:  J Proteome Res       Date:  2020-01-17       Impact factor: 4.466

7.  Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.

Authors:  Paul J F Rider; Ifeanyi K Uche; Larissa Sweeny; Konstantin G Kousoulas
Journal:  Curr Clin Microbiol Rep       Date:  2019-11-26

8.  Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.

Authors:  Alena C Jaime-Ramirez; Jun-Ge Yu; Enrico Caserta; Ji Young Yoo; Jianying Zhang; Tae Jin Lee; Craig Hofmeister; John H Lee; Bhavna Kumar; Quintin Pan; Pawan Kumar; Robert Baiocchi; Theodoros Teknos; Flavia Pichiorri; Balveen Kaur; Matthew Old
Journal:  Mol Ther Oncolytics       Date:  2017-05-10       Impact factor: 7.200

Review 9.  Lifting the innate immune barriers to antitumor immunity.

Authors:  Carla V Rothlin; Sourav Ghosh
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

10.  Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation.

Authors:  Mitra Nair; Maninder Khosla; Yoshihiro Otani; Margaret Yeh; Flora Park; Toshihiko Shimizu; Jin Muk Kang; Chelsea Bolyard; Jun-Ge Yu; Yeshavanth Kumar Banasavadi-Siddegowda; Gonzalo Lopez; Balveen Kaur; Raphael E Pollock; Tae Jin Lee; Matthew Old; Ji Young Yoo
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.